FDA Grants Poseida’s P-BCMA-101 RMAT Status for Treatment of Multiple Myeloma
News
The U.S. Food and Drug Administration (FDA) has granted P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy and lead product candidate, the Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of relapsed ... Read more